IL162433A0 - Modified polypeptide - Google Patents

Modified polypeptide

Info

Publication number
IL162433A0
IL162433A0 IL16243302A IL16243302A IL162433A0 IL 162433 A0 IL162433 A0 IL 162433A0 IL 16243302 A IL16243302 A IL 16243302A IL 16243302 A IL16243302 A IL 16243302A IL 162433 A0 IL162433 A0 IL 162433A0
Authority
IL
Israel
Prior art keywords
growth hormone
modified polypeptide
modified
binding domain
receptor
Prior art date
Application number
IL16243302A
Other languages
English (en)
Original Assignee
Asterion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asterion Ltd filed Critical Asterion Ltd
Publication of IL162433A0 publication Critical patent/IL162433A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
IL16243302A 2001-12-14 2002-12-06 Modified polypeptide IL162433A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0130052A GB2384001B (en) 2001-12-14 2001-12-14 Chimeric growth hormone-growth hormone receptor proteins
PCT/GB2002/005523 WO2003070765A2 (en) 2001-12-14 2002-12-06 Growth hormone fusion protein

Publications (1)

Publication Number Publication Date
IL162433A0 true IL162433A0 (en) 2005-11-20

Family

ID=9927705

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16243302A IL162433A0 (en) 2001-12-14 2002-12-06 Modified polypeptide
IL162433A IL162433A (en) 2001-12-14 2004-06-10 Growth hormone receptor antagonist
IL200659A IL200659A0 (en) 2001-12-14 2009-09-01 Modified polypeptide

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL162433A IL162433A (en) 2001-12-14 2004-06-10 Growth hormone receptor antagonist
IL200659A IL200659A0 (en) 2001-12-14 2009-09-01 Modified polypeptide

Country Status (19)

Country Link
US (2) US7524649B2 (pl)
EP (2) EP1456385B1 (pl)
JP (2) JP5248734B2 (pl)
KR (3) KR20040083470A (pl)
CN (2) CN100558899C (pl)
AT (1) ATE541935T1 (pl)
AU (1) AU2002366325B2 (pl)
CA (1) CA2468439A1 (pl)
ES (1) ES2378424T3 (pl)
GB (2) GB2384001B (pl)
HU (1) HUP0402496A3 (pl)
IL (3) IL162433A0 (pl)
MX (1) MXPA04005675A (pl)
NZ (1) NZ533550A (pl)
PL (1) PL210714B1 (pl)
RU (2) RU2346047C2 (pl)
SG (1) SG160205A1 (pl)
WO (1) WO2003070765A2 (pl)
ZA (2) ZA200404488B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290170A2 (en) * 2000-06-16 2003-03-12 Asterion Limited Binding agents: chimeric ligand/receptor proteins
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP1771467A2 (en) * 2004-07-26 2007-04-11 Asterion Limited Linkers
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
GB0606946D0 (en) * 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
GB0618082D0 (en) * 2006-09-14 2006-10-25 Asterion Ltd Growth factor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
GB0717985D0 (en) * 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
GB0719818D0 (en) 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
WO2009077731A2 (en) * 2007-12-19 2009-06-25 Asterion Limited Prolactin fusion proteins
WO2011085070A2 (en) * 2010-01-06 2011-07-14 Virginia Tech Intellectual Properties, Inc. Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
JP5412323B2 (ja) 2010-02-26 2014-02-12 日東電工株式会社 貼付製剤
GB201104285D0 (en) 2011-03-15 2011-04-27 Asterion Ltd Modified receptor fusion proteins
EP2606908A1 (en) 2011-12-19 2013-06-26 Ipsen Pharma S.A.S. Novel pharmaceutical composition for a long acting growth hormone fusion protein (LAGH)
DK2809400T3 (en) 2012-02-03 2019-03-04 Antisense Therapeutics Ltd COMBINATION THERAPY INCLUDING A GROWTH HORMON VARIANT AND AN OIGONUCLEOTIDE BINDING TO THE GROWTH HORMON RECEPTOR
CN105229035A (zh) * 2013-03-11 2016-01-06 诺和诺德保健股份有限公司 生长激素化合物
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
EP3820497A4 (en) * 2018-07-11 2022-03-23 Ohio University Peptide-based inhibitors of growth hormone action and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5958879A (en) * 1989-10-12 1999-09-28 Ohio University/Edison Biotechnology Institute Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
HUT69963A (en) * 1990-12-13 1995-09-28 Upjohn Co Non-naturally-occuring fusion proteins and process for preparing them
JP3417558B2 (ja) * 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
IT1251895B (it) * 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
DK0851925T3 (da) * 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ATE216723T1 (de) * 1996-02-13 2002-05-15 Japan Chem Res Hormones de croissance humaines mutantes et leur utilisation
JP2000516472A (ja) 1996-08-16 2000-12-12 メディカル リサーチ カウンシル 組織特異的遺伝子発現を与える自己複製型エピソーム性発現ベクター
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1290170A2 (en) * 2000-06-16 2003-03-12 Asterion Limited Binding agents: chimeric ligand/receptor proteins
GB2384001B (en) * 2001-12-14 2004-02-04 Asterion Ltd Chimeric growth hormone-growth hormone receptor proteins

Also Published As

Publication number Publication date
PL210714B1 (pl) 2012-02-29
CN101638437A (zh) 2010-02-03
GB2389115B (en) 2005-03-16
IL200659A0 (en) 2010-05-17
HUP0402496A2 (hu) 2005-03-29
JP2010043100A (ja) 2010-02-25
ATE541935T1 (de) 2012-02-15
SG160205A1 (en) 2010-04-29
HUP0402496A3 (en) 2012-03-28
GB2384001A (en) 2003-07-16
EP1456385A2 (en) 2004-09-15
KR20040083470A (ko) 2004-10-02
AU2002366325B2 (en) 2008-04-24
ZA200600149B (en) 2006-10-25
RU2004117777A (ru) 2005-05-10
WO2003070765A2 (en) 2003-08-28
RU2346047C2 (ru) 2009-02-10
GB2384001B (en) 2004-02-04
KR20070108254A (ko) 2007-11-08
NZ533550A (en) 2006-02-24
ES2378424T3 (es) 2012-04-12
CN100558899C (zh) 2009-11-11
EP1456385B1 (en) 2012-01-18
US20050123558A1 (en) 2005-06-09
US7524649B2 (en) 2009-04-28
AU2002366325A1 (en) 2003-09-09
ZA200404488B (en) 2006-03-29
PL371313A1 (pl) 2005-06-13
CN1604965A (zh) 2005-04-06
HK1070669A1 (en) 2005-06-24
US20090239801A1 (en) 2009-09-24
CA2468439A1 (en) 2003-08-28
GB0130052D0 (en) 2002-02-06
KR100879553B1 (ko) 2009-01-22
GB0320479D0 (en) 2003-10-01
MXPA04005675A (es) 2005-04-19
EP2365085A1 (en) 2011-09-14
IL162433A (en) 2011-09-27
KR100848802B1 (ko) 2008-07-28
WO2003070765A3 (en) 2003-11-27
JP5248734B2 (ja) 2013-07-31
GB2389115A (en) 2003-12-03
KR20060106862A (ko) 2006-10-12
JP2005525106A (ja) 2005-08-25
RU2008118104A (ru) 2009-11-20

Similar Documents

Publication Publication Date Title
IL200659A0 (en) Modified polypeptide
IL222149B (en) A protein comprising a modified version of the fc region of a human antibody with increased binding affinity to fcrn
WO2000018932A3 (en) Receptor based antagonists and methods of making and using
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
WO1998038212A3 (en) Chimeric polypeptides containing chemokine domains
PL1833847T3 (pl) Polipeptydy fuzyjne IGF-1 oraz ich zastosowanie terapeutyczne
IL161016A (en) Polypeptides capable of ang-2 binding
AU2002250049A8 (en) Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
MXPA00003885A (es) Quimiocinas con modificiaciones de la terminacion amino.
AU2002357427A1 (en) Peptide or protein containing a c'-d loop of the cd28 receptor family
AU3087599A (en) Human appetite control by glucagon-like peptide receptor binding compounds
MXPA02002767A (es) Usos terapeuticos del polipeptido m3.
GB9924951D0 (en) Novel polypeptide
AU2002214914A1 (en) A novel polypeptide- t1/st2 receptor binding protein 10.23 and the polynucleotide encoding said polypeptide
AU1510801A (en) A novel polypeptide, a human s100 calcium binding protein 21 and the polynucleotide encoding the polypeptide
AU2001293639A1 (en) A novel polypeptide-human tnfr/ngfr protein 15 that contains cytochrome c structural domain and the polynucleotide encoding said polypeptide
EP0572122A3 (en) C-terminal modified osteogenic growth polypeptides.
GB9923888D0 (en) Novel polypeptide
AU4405201A (en) A novel polypeptide-human protein 17 containing chromo domain and the polynucleotide encoding said polypeptide
AU8149001A (en) A novel polypeptide, a human TNFR/NGFR protein containing cytochrome C domain and the ploynucleotide encoding the polypeptide
AU2001295401A1 (en) A novel polypeptide-homo tnfr/ngfr protein 9.02 containing cytochrome c structural domain and polynucleotide encoding said polypeptide
AU8953101A (en) A novel peptide---human tnfr/ngfr protein including cytochrome c domain and the polynucleotide coding this novel peptide
ATE404576T1 (de) Neuartiges polypeptid und dessen kodierende nukleinsäuren
AU1031502A (en) A novel polypeptide human - glutamate receptor interacting protein 11.55 and a polynucleotide encoding the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed